Cardiol Therapeutics (CRDL) Liabilities and Shareholders Equity (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $22.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 29.1% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.6 million (down 12.38% YoY) and the FY2025 annual result came in at $16.9 million, down 25.74% from the prior year.
• Liabilities and Shareholders Equity rose to $22.9 million in Q1 2026, from $16.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $62.7 million in Q1 2022 to a low of $9.4 million in Q3 2025.
• A 5-year average of $30.1 million and a median of $23.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 107.93% — and 2024, when it plunged 60.01%.
• Tracing CRDL's Liabilities and Shareholders Equity over 5 years: stood at $45.7 million in 2022, then slumped by 41.01% to $27.0 million in 2023, then declined by 15.39% to $22.8 million in 2024, then fell by 25.74% to $16.9 million in 2025, then soared by 35.21% to $22.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $22.9 million (Q1 2026), $16.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.